Characteristics of patients with CBF AML
| . | Auto-SCT . | Allo-SCT . | ||||
|---|---|---|---|---|---|---|
| t(8;21)(n = 61), no. . | inv(16)(n = 17), no. . | P . | t(8;21)(n = 194), no. . | inv(16)(n = 66), no. . | P . | |
| Median age, y (range) | 44 (17-68) | 37 (19-61) | .59 | 39 (16-70) | 34 (16-64) | .054 |
| Median WBC, g/L (range) | 8.8 (0.2-94) | 33 (2.1-199) | .02 | 11 (.6-366) | 53 (1.8-284) | < .001 |
| Sex | ||||||
| Male | 41 | 12 | .79 | 117 | 40 | .93 |
| Female | 20 | 5 | 74 | 26 | ||
| No. of induction chemotherapy at diagnosis of AML | ||||||
| 1 course | 48 | 15 | .72 | 125 | 55 | .002 |
| > 1 or failure* | 11 | 2 | 56 | 7 | ||
| Additional cytogenetic abnormalities | ||||||
| None | 53 | 15 | > .999 | 153 | 54 | .61 |
| Positive | 8 | 2 | 41 | 12 | ||
| Disease status at SCT | ||||||
| CR | 55 | 16 | > .999 | 108 | 52 | < .001 |
| Not in CR | 6 | 1 | 85 | 11 | ||
| CR1 | 43 | 13 | .98 | 49 | 21 | .29 |
| CR2 | 7 | 1 | 45 | 26 | ||
| CR3 | 0 | 1 | 5 | 4 | ||
| Conditioning regimen | ||||||
| TBI | 0 | 1 | .22 | 118 | 47 | .078 |
| Not TBI | 61 | 16 | 71 | 16 | ||
| . | Auto-SCT . | Allo-SCT . | ||||
|---|---|---|---|---|---|---|
| t(8;21)(n = 61), no. . | inv(16)(n = 17), no. . | P . | t(8;21)(n = 194), no. . | inv(16)(n = 66), no. . | P . | |
| Median age, y (range) | 44 (17-68) | 37 (19-61) | .59 | 39 (16-70) | 34 (16-64) | .054 |
| Median WBC, g/L (range) | 8.8 (0.2-94) | 33 (2.1-199) | .02 | 11 (.6-366) | 53 (1.8-284) | < .001 |
| Sex | ||||||
| Male | 41 | 12 | .79 | 117 | 40 | .93 |
| Female | 20 | 5 | 74 | 26 | ||
| No. of induction chemotherapy at diagnosis of AML | ||||||
| 1 course | 48 | 15 | .72 | 125 | 55 | .002 |
| > 1 or failure* | 11 | 2 | 56 | 7 | ||
| Additional cytogenetic abnormalities | ||||||
| None | 53 | 15 | > .999 | 153 | 54 | .61 |
| Positive | 8 | 2 | 41 | 12 | ||
| Disease status at SCT | ||||||
| CR | 55 | 16 | > .999 | 108 | 52 | < .001 |
| Not in CR | 6 | 1 | 85 | 11 | ||
| CR1 | 43 | 13 | .98 | 49 | 21 | .29 |
| CR2 | 7 | 1 | 45 | 26 | ||
| CR3 | 0 | 1 | 5 | 4 | ||
| Conditioning regimen | ||||||
| TBI | 0 | 1 | .22 | 118 | 47 | .078 |
| Not TBI | 61 | 16 | 71 | 16 | ||
Correlation between the two groups was examined.
WBC indicates white blood cell count; g/L, 109/L; CR1, first complete remission; and CR2 or 3, second or third CR.
More than 1 or failure includes patients who did not achieve complete remission after first course of induction chemotherapy, and those who were resistant to induction chemotherapy.